Soft Tissue Sarcoma

Finish this week of #SarcomaAwarenessMonth by watching this case-based discussion by @CrisyRoland @emilykeungMD @xrtcell Jay Wonder, MD, & Miheala Druta, MD that includes the role of sentinel lymph node biopsy in the management of #SoftTissueSarcoma. https://t.co/SCJHnXXQwr (@SocSurgOnc)

😳it just never ends ... "Proton therapy is also beneficial for cancers of the brain and spine, breast, esophagus, head and neck, liver, lung, eye, pancreas, and prostate, as well as lymphomas and soft tissue sarcomas." https://t.co/FsJk2DSFEU (@HenningWillers)

#Biomarkers of response are crucial in treating patients with #SoftTissueSarcomas. Bui et al evaluate circulating tumor DNA as a biomarker and find that it represents a promising biomarker for monitoring treatment response. https://t.co/h9vfZ6MzMl @NamBuiMD @everettmoding (@CCR_AACR)

Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival | Clinical Cancer Research | American Association for Cancer Research ⁦@CCR_AACR⁩ ⁦@AACR⁩ https://t.co/leu9uCiWcB (@VivekSubbiah)

Doxorubicin + zalifrelimab & balstilimab produced a favorable 6-month PFS rate in pts w/ difficult-to-treat soft tissue sarcoma subtypes unlikely to respond to doxorubicin or immune checkpoint inhibitor monotherapy. @breelynwilkyMD @CUCancerCenter #scmsm https://t.co/DIwIvhUMeS (@OncLive)

Doxorubicin + zalifrelimab & balstilimab produced a favorable 6-month PFS rate in pts w/ difficult-to-treat soft tissue sarcoma subtypes unlikely to respond to doxorubicin or immune checkpoint inhibitor monotherapy. @breelynwilkyMD @CUCancerCenter #scmsm https://t.co/DLu9PX77zl (@OncLive)

Dermatofibrosarcoma protuberans (@SamehFayekSaleh)

Need of the hour! Need to see much more of this to improve outcomes of soft tissue sarcoma! (@DrJaymin)

Dermatofibrosarcoma protuberans 👌🏻 (@GiovArn)

What kind of #sarcoma did Brad have? My 18 year old son Reese has #epithelioid sarcoma obstructing his urethra. University of Miami Sylvester #Cancer Institute chemo Round 4 on 7/3. I feel desperate. Week 4 of 5 radiation currently. Dr.Dhir Alex’s Place. I can’t find survivors. (@STACISMAIL)

The addition of pazopanib to neoadjuvant chemotherapy and radiotherapy was associated with a higher rate of wound complications in patients with non-rhabdomyosarcoma soft tissue sarcoma. @RLRandallMD @UCDavisHealth #oncology #scmsm https://t.co/dahyXAeHZ4 (@OncLive)

The addition of nivolumab and ipilimumab to cabozantinib led to an improvement in disease control rate and progression-free survival vs cabozantinib alone in patients with metastatic soft tissue sarcoma. @bvantine1 #ASCO23 #scmsm https://t.co/L2XDmf5V2X (@OncLive)

CD34 in a Dermatofibrosarcoma Protuberans (DFSP), storiform pattern. (@gerardo_cazzato)

Carthwheel pattern seen in dermatofibroma and dermatofibrosarcoma CD 34 to differentiate benign from malignant (@SalmanSiddiq3)

The addition of nivolumab and ipilimumab to cabozantinib led to an improvement in disease control rate and progression-free survival vs cabozantinib alone in patients with metastatic soft tissue sarcoma. @bvantine1 #ASCO23 #scmsm https://t.co/y2zTzmIEVd (@OncLive)

.@RLRandallMD, of @UCDavisHealth, discusses the use of neoadjuvant pazopanib in pts w/ non-rhabdomyosarcoma soft tissue sarcoma, expanded on findings from the subgroup analysis of ARST1321, and detailed the implications of these findings. #oncology #scmsm https://t.co/S59nr6D5kw (@OncLive)

Hear @bvantine1, the leader of the @WashUOnc sarcoma program discuss Soft Tissue Sarcoma Updates from the West Conference. @WUSTLmed @WUDeptMedicine @SitemanCenter @WUSTLdbbs @VuMedi https://t.co/pEEcF6D49k (@WashUOnc)

Most high gr serous ca arise from STICs in FTs & are monoclonal; low grades are polyclonal However, like prim peritoneal tumors (DMPM; DSRCT), in EOC, -ascites can be present in any stage -peritoneal spread is not metastatic but locoregional dz all other sec PM➡️stage IV (@PSOGI_EC)

SI on RETROPERITONEAL SARCOMA Pelvic soft tissue sarcomas @SinzianaDumitra @FioreDoc @ESSOnews @me4_so @SBonvalot @rutkowskip1972 @SWexner @3isac @HelenMohan1 @dr_samehhany81 @BASO_ACS @EYSAC1 @TARPSWG @ctosociety @DeliaCortesGuir @BoganiGiorgio https://t.co/iM8PJtFdXs (@ejsotweets)

Pazopanib Associated With Higher Wound Complication Rates in Non-rhabdomyosarcoma Soft Tissue Sarcoma @RLRandallMD @UCDavisHealth #scmsm #oncology https://t.co/tDk2J1WT51 (@OncLive)

Epithelioid sarcoma (@WidedAjouli)

Dermatofibrosarcoma protuberans - malignant tumor of connective tissue origin, usually slows down its growth and spread into the surrounding tissues. Distant metastases are rare. Typically, dermatofibrosarcoma protuberans is localized in the body region or the upper body. (@Feridee_11)

Cabozantinib Plus Nivolumab/Ipilimumab Generates PFS and DCR in Metastatic Soft Tissue Sarcoma @bvantine1 @ASCO #ASCO23 #scmsm https://t.co/jftf2zJQR5 (@OncLive)

.@bvantine1, of @SitemanCenter, highlighted insights on the use of cabozantinib w/ PD-1 & CTLA-4 inhibition versus cabozantinib in metastatic soft tissue sarcoma LIVE at #ASCO23.. To get the latest updates from the @ASCO Annual Meeting, check back here: https://t.co/Jt115EnnnO (@OncLive)

Dermatofibrosarcoma (@WidedAjouli)

Dermatofibrosarcoma, seems to be invading the adipose tissue (@Talha_K_Khan)

Epithelioid sarcoma, CAM5,2 ? (@BMollamehmet)

Hemangiopericytoma (@Marytresa4)

Contemporary role of amputation for patients with extremity soft tissue sarcoma @ChirSarcomi_INT @sandro_pasquali @alegronchi @FioreDoc @ESSOnews @BASO_ACS @TARPSWG @OncologyAdvance @OncoAlert @SoMe4sarcoma @ItaSarcomaGroup @Sarcoma_papers @SARCtrials https://t.co/kS0z0s4rCe (@ejsotweets)

Pleomorphic liposarcoma (epithelioid type). (@RZitwer)

European Commission grants #OrphanDrug designation to #PharmaMars #Lurbinectedin for the treatment of #SoftTissueSarcoma $PHM https://t.co/jZgw2c3SiW (@1stOncology)

It was a pleasure to chair the #SPAGN2023 session on research into soft tissue sarcoma subtypes this morning. Thank you Robin, Bernd, Peter and @JTrentMDPhD for the lively conversation! @sarcomapatients (@Sorrel_Bickley)

Dermatofibrosarcoma protuberans ? (@Drojay4)

1/2 Differentials of pelvic mass in a child - ⏺ Germ cell tumor ( ovary/sacrococcygeal) ⏺️ Rhabdomyosarcoma (genito urinary) ⏺️ Neuroblastoma ⏺️Ewings sarcoma ⏺️lymphoma ⏺️ Desmoplastic small round cell tumor ⏺️ Chondrosarcoma (@Satyayadav__)

More evidence of prognostic & potential predictive importance of #hypo - now in #softtissuesarcoma Also valuable transcriptomic resource 👏🏽 @BrJCancer @UoM_DCS @MCRCnews @ForkerLaura @ManchesterBRC @iatmcr @CatharineWest3 @CindyBillingham @ChristieLibrary https://t.co/yHKyORLhSb (@achoud72)

Dermatofibrosarcoma protuberans with giant cell fibroblastoma pattern, CD34+. Great case (@RZitwer)

@WTapMD Respected Dr.Tap I would request you grant me the invaluable opportunity to observe and learn from you in April 2023, I am a graduate practicing physician in India with an interest in Soft Tissue Sarcomas, and being a survivor myself I am very keen on learning. Thank You (@ParthMunjal6)

First series of advanced #epithelioid sarcoma, India. @smarcb1 @SachinSarcoma @RashiKapoor17 1. Misdiagnosis is quite common. 2. Advanced disease with lymph node involvement 3. Tazemetostat - Only a few could access it. https://t.co/1FA18Pis0C (@samdoc_mamc)

@danhdtruong discussing preclinical data for possibility of using androgen receptors as target for treatment of #DSRCT 🚨new DSRCT subtypes based on AR or neuroendocrine signatures @MDAndersonNews #CTOS2022 #CTOSTweeTOS @ctosociety @A_Duensing @OncoAlert (@pawel_sobczuk)

Is androgen receptor a target for desmoplastic small round cell tumor? Maybe…. Dr Danh Truong @ctosociety #CTOS2022 #CTOSTweeTOS #ctos22 @OncoAlert @EmilyJonczak @GinaDAmatoMD1 @SteveBialickDO @PriscilaBCMD @SolangeSV (@JTrentMDPhD)

Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden @JournalCancer @OncoAlert https://t.co/a3vLZFzwSW (@VivekSubbiah)

Targeting desmoplastic small round cell #sarcoma: the androgen receptor (AR) promotes tumor growth, and AR antagonist therapy reduces tumor burden. @richardriedelmd recommends Lamhamedi-Cherradi SE’s paper in @NatureComms. #DSRCT #SarcomaAwarenessMonth https://t.co/H0IBbjuqPC (@Facultyopinions)